Renin-angiotensin system and cardiovascular risk

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Endocrinology

Background:

• The renin-angiotensin system (RAS) is a key regulator of cardiovascular and renal function.
• Emerging research highlights novel therapeutic targets within the RAS.
• RAS blockade demonstrates significant benefits beyond its antihypertensive effects.

Purpose of the Study:

• To review the multifaceted therapeutic effects of RAS blockade.
• To emphasize the role of RAS inhibitors in managing cardiovascular and renal diseases.
• To discuss the impact of RAS blockade on diabetes and associated complications.

Main Methods:

• Review of basic research findings on the RAS.
• Analysis of clinical data on angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
• Synthesis of evidence regarding the antiatherosclerotic, anti-inflammatory, and antiproliferative properties of RAS blockade.

Main Results:

• RAS blockade exhibits potent antiatherosclerotic effects through multiple mechanisms.
• Angiotensin converting enzyme inhibitors and angiotensin receptor blockers are first-line treatments for hypertension and renal disease.
• RAS blockade reduces atrial fibrillation, stroke, and delays type 2 diabetes onset.
• These therapies prevent cardiovascular and renal events in diabetic patients.

Conclusions:

• RAS blockade is a cornerstone in reducing cardiovascular risk.
• Therapeutic strategies targeting the RAS offer broad benefits for cardiovascular and renal health.
• The pleiotropic effects of RAS inhibitors underscore their importance in modern medicine.